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Introduction
Prostatecanceristhe mostcommoncancer(otherthannonmelanomaskincancer)inCanadianmen. 1 Itispredictedthat 26500newcasesofprostatecancerwillbediagnosedin Canadain2012(i.e.,121per100000population)andthat 4000menwilldieofthedisease.
1 Thereportedincidence ofprostatecancerinCanadahasrisensince1980,whichis probablyareflectionofimproveddiagnosis;however,the rateofdeathfromthediseasehasbeenindeclinesincethe mid-1990s. 1 Hormonalmanipulation,basedonandrogen deprivationandanti-androgentherapy,istheinitialcornerstoneofmedicalmanagementoflocallyadvancedor metastaticprostatecancer. 2 Ondiseaseprogressiondespite hormonalmanipulation,thediseaseisdefinedascastrationresistantprostatecancer(CRPC;oftenreferredtoinearlier literatureashormone-refractoryprostatecancer). 3 Mostmen (90%)withCRPChavemetastaticdisease(mCRPC),andmay ormaynothavepotentiallydebilitatingsymptoms. 3 Lessthanadecadeago,mCRPCwasdeemedtobea "chemoresistant"disease,withapoorprognosis.Mitoxantrone, incombinationwithprednisoneorprednisolone,wascommonlyused,butprovidedonlypalliationofsymptomswithoutimprovementinsurvival. 4 ThenthelandmarkTAX327 trial,publishedin2004,showedthatacourseofchemotherapybasedonthetaxanedocetaxelcouldextendsurvival formenwithmCRPC(versusmitoxantrone-basedchemotherapy). 5 Withthistrial,prostatecancerenteredthechemotherapyage.Forseveralyears,docetaxelremainedthe onlychemotherapytoofferasurvivalbenefitinthissetting. Then,in2010itwasreportedthatmenwithmCRPCwho progressedduringorafterdocetaxelcouldgainafurther survivalbenefitfromasecondlineofchemotherapy,based onanothertaxane-cabazitaxel. 6 Onceagain,thepalliative chemotherapyagentmitoxantronewasthecomparator.
Thisarticleconsiderstheevidencebaseforeachofthe chemotherapylinesassociatedwithextendedsurvival,and theimplicationsforpatientcare,withspecificreferenceto clinicalpracticeinCanada.
First-line chemotherapy phase III evidence
In TAX327, 1006 men with mCRPC were randomized to prednisone 10 mg/day plus weekly or 3-weekly docetaxel or 3-weekly mitoxantrone (Fig. 1) . 5 At updated analysis, median overall survival was 19.2 months with 3-weekly docetaxel, 17.8 months with weekly docetaxel and 16.3 months with mitoxantrone (Fig. 2) . 7 Other outcomes are presented in Fig. 3 . 5, 7 The most common grade 3/4 adverse event was neutropenia (3-weekly docetaxel, 32%; weekly docetaxel, 2%; mitoxantrone, 22%), but febrile neutropenia was rare (3-weekly docetaxel, 3%; weekly docetaxel, 0%; mitoxantrone, 2%). 5 More docetaxel recipients than mitoxantrone recipients experienced at least one serious adverse event (3-weekly docetaxel, 26%; weekly docetaxel, 29%; mitoxantrone, 20%). Based on their findings, the investi-gatorssuggestedthat3-weeklydocetaxelplusprednisone improvedsurvival,prostate-specificantigen(PSA)response, painresponseandqualityoflifeversusmitoxantroneplus prednisone.
patient selection/referral
A retrospective analysis of the outcome of docetaxel treatment in 145 patients at a single centre suggested that men with no/minimal pain at the outset of chemotherapy had longer survival times than those with mild or moderate/severe pain. 8 Furthermore, it has been reported that once a new lesion is detected on bone scan, an asymptomatic patient with mCRPC is likely to develop symptoms within a median of just 3 months. 9 These findings suggest that prompt referral of patients with mCRPC, rather than a policy based on waiting for symptoms, is likely to benefit survival. 10 Guidelines from the Canadian Urologic Oncology Group (CUOG) and the Canadian Urological Association (CUA) state that docetaxel plus prednisone is the standard of care for men with mCRPC, and the 3-weekly regimen is recommended for patients with clinical or biochemical evidence of disease progression and evidence of metastases. 3 To ensure timely and appropriate initiation of chemotherapy, the guidelines emphasize that patients with advanced prostate cancer should receive an early referral for consideration of docetaxel, and that their outcomes will be optimized through a multidisciplinary approach to their care.
Looking specifically at patients who have mCRPC but, for the time being at least, remain pain free, the CUOG/CUA guidelines recommend an individualized approach, taking into account the patient's clinical status and preferences. 3 Prostate cancer guidelines from the National Comprehensive Cancer Network (NCCN) also stipulate that docetaxel may be considered for asymptomatic men with mCRPC who have signs of rapid progression or soft tissue/visceral metastases. 
Second-line chemotherapy

Early evidence
Once docetaxel-based chemotherapy became established as the standard of care for mCRPC, several regimens were investigated for their potential in the post-docetaxel setting. Thefirsttoshowasurvivalbenefitwascabazitaxel. 6 The selectionofanothertaxanewasnotentirelyexpected.Crossresistancehasbeenshownbetweendifferentmembersof thisdrugclass,sodiseaseprogressiononorshortlyafter docetaxeltreatmentislikelytopredictalackofresponse toasecondtaxane. 12 However,cabazitaxelhasalowaffinityfortheadenosinetriphosphate(ATP)drugeffluxpump P-glycoproteinassociatedwithresistancetodocetaxel,and theagentwasfoundtobeactiveagainstcelllineswith demonstratedtaxaneresistance. 13, 14 Basedonthesefindings,cabazitaxelwasselectedfor clinicalinvestigation.Thenoveltaxanewasfoundtohave anti-tumoractivityandgoodtolerabilityinaphaseItrial in25patientswithsolidtumors(including8withprostate cancer), 14 andaphaseIItrialin71womenwithtaxane-resistantbreastcancershoweda14%responserate,anda 3%rateoffebrileneutropenia. 13 
phase III data
The key phase III clinical data on cabazitaxel emerged from the TROPIC trial, conducted in 26 countries in North and South America, Eastern and Western Europe and Asia, and involved 755 patients with mCRPC who had already receiveddocetaxel-basedchemotherapy. 6 Aboutone-third ofthepatientpopulationhadalreadyreceived2ormore coursesofchemotherapy,andtwo-thirdshaddeveloped progressivediseaseeitherduringorwithin3monthsof docetaxeltreatment.Inaddition,abouthalfhadmeasurabledisease,and25%hadvisceralmetastases,indicating mCRPCwithapoorprognosis. Thepatientswererandomizedtoreceivecabazitaxelor mitoxantrone,plusprednisoneorprednisolone10mg/day (Fig.4) . 6 Aswellasimprovingoverallsurvivalacrossthe studypopulation(cabazitaxel15.1months;mitoxantrone 12.7months; Fig.5 ),objectivetumorresponseandPSA response (Fig.6 ),subgroupanalysissuggestedthatcabazitaxelwasbeneficialforolderandyoungerpatients(age <65vs.≥65years),andinthepresenceorabsenceofpain atbaseline. 6 Inanupdatedanalysis,publishedin2011,it wasestimatedthattheprobabilityofsurvivalat24months was28%inthecabazitaxelgroup,comparedwith17% withmitoxantrone. 15 Themostcommon(≥5%)grade3/4sideeffectswere neutropenia,leucopenia,anemia,febrileneutropeniaand diarrhea. 6 Grade3/4neutropeniawasrecordedin82%of cabazitaxeland58%ofmitoxantronerecipients,withfebrile neutropeniain8%and1%,respectively.Diarrheaatany 6 Moreover,it wasnoted,inacommentarypublishedconcurrentlywith theTROPICtrial,thatmanagementoffebrileneutropenia variedconsiderablybetweenthevariousTROPICcentres acrosstheworld,afactorthatmighthavecontributedtothe excessmortalityinthecabazitaxelgroup. 16 Indeed,analysis ofthedatafromtheNorthAmericancentres(n=235)showed thatonly1patient(<1%)ineachtreatmentgroupdiedasa resultoftreatmentsideeffects. 17 Thecommentaryauthors recommendthatcentresofferingcabazitaxelshouldhave well-structuredplansinplaceforthemanagementofboth diarrheaandfebrileneutropenia. (Theimportanceofproactivemanagementofcabazitaxelsideeffectsisdiscussedby  SperlichandSaadinthissupplementonpageS18. 18 ) InJune2011,basedonthefindingsoftheTROPICtrial, 6 HealthCanadaapprovedcabazitaxelforthetreatmentof mCRPCinmenpreviouslytreatedwithdocetaxel. 19 
Early-access program
Following the TROPIC trial, an international cabazitaxel early-access program was established to collect data on treatment safety and patients' quality of life. 20 The participating countries are shown in Fig. 7 . 20 Interim data from the UK arm of this study (based on up to 4 treatment cycles), showed improvement in pain control with continuing treatment (Fig. 8) , stable scores for anxiety/depression, mobility and self-care, a 4.9% incidence of febrile neutropenia and a 2.4% incidence of diarrhea. Preliminary analysis of data from the Canadian arm of the early-access program (33 patients, median age 65years,>50%received≥5cycles)haveshownimprovementinpain-thepainsubscaleoftheFunctionalAssessment CancerTherapy-Prostate(FACT-P)questionnairefoundthat painimprovedinthefirst4cyclesofcabazitaxel,andpresentpainintensityscoresimproveddespiteuseofanalgesia. 21 Theincidenceofgrade3/4diarrheawas3%,andno treatment-relateddeathshavebeenreported. 
Implications for patient care
Conclusion
Aftermanyyearsofapparent"chemoresistance,"mCRPC hasemergedintothechemotherapyage,initiallywithone lineofchemotherapy, 4 andnowatwo-lineapproachbased ondocetaxelfollowedbycabazitaxel, 6 bothofferingasurvivaladvantagetoapopulationthatpreviouslyonlyhad accesstosymptompalliation.Furtherdataareexpected soonfromthecabazitaxelearly-accessscheme,whichwill shedmorelightontheclinicalimplicationsofthetwo-line chemotherapeuticpathway.
Optimaluseofdocetaxelandcabazitaxelwilldepend onamultidisciplinaryapproachtopatientcare,withinsight fromurologyandoncology,tofacilitateeffectivepatient selection,timelytreatmentinitiationandproactivetoxicity management.
